Back to News
Market Impact: 0.15
Rakovina Adds Yale Scientist Bindra To Advisory Board As DDR Pipeline Advances
Source: Nasdaq
Healthcare & BiotechArtificial IntelligenceManagement & Governance
Rakovina Therapeutics appointed Dr. Ranjit Bindra, Scientific Director of the Yale Brain Tumor Center, to its Scientific Advisory Board. The appointment supports the company's advancement of its AI-driven oncology pipeline, though no clinical, financial, or development milestone was disclosed.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
Ticker Sentiment
RKV0.45
More News
- Amgen (AMGN) Bets on MariTide to Crack $120 Billion Obesity Market
- BTIG cuts Acumen Pharmaceuticals stock price target to $1 on trial results
- Aehr Test Systems earnings on deck amid AI chip boom
- Ryanair warns of €2 bln higher fuel bill next year as H1 profit falls 15%
- Jefferies raises West Pharmaceutical stock price target on HVP growth
- BMO raises Equinix stock price target on strong demand and pricing